Commercial sector

SUD Pharmacotherapy Developers

Companies developing or commercializing medications (small molecules, biologics, or novel mechanisms) for the treatment of opioid, stimulant, alcohol, or cannabis use disorders. This includes approved formulations of buprenorphine, methadone, and naltrexone, as well as clinical-stage programs targeting novel receptors (kappa, orexin, GLP-1, neuroimmune, psychedelic-derived) or repurposed agents for stimulant and cannabis use disorders.

Companies55
Commercial products151
Technology classes8
Countries12
Patents945

Profiled companies

Products
  • Indivior logo
    Indivior
    United States8
  • Orexo logo
    Orexo
    Sweden9
  • Alkermes logo
    Alkermes
    Ireland2
  • Braeburn logo
    Braeburn
    United States1
  • Ethypharm logo
    Ethypharm
    France2
  • Sparian Biosciences logo
    Sparian Biosciences
    United States5

+ 49 more

← Back to what’s inside this report